Prosperity Financial Group Inc. Has $226,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Prosperity Financial Group Inc. lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 64.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,388 shares of the company’s stock after selling 2,557 shares during the period. Prosperity Financial Group Inc.’s holdings in Zoetis were worth $226,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Darwin Wealth Management LLC acquired a new position in Zoetis during the 3rd quarter valued at about $31,000. Capital Performance Advisors LLP acquired a new position in Zoetis during the 3rd quarter valued at about $33,000. Dunhill Financial LLC boosted its stake in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Atlantic Edge Private Wealth Management LLC boosted its stake in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the last quarter. Finally, Quarry LP lifted its position in shares of Zoetis by 45.9% during the 3rd quarter. Quarry LP now owns 305 shares of the company’s stock worth $60,000 after buying an additional 96 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,862 shares of company stock worth $312,254. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ZTS. Piper Sandler lifted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Finally, Morgan Stanley lowered their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $215.90.

Zoetis Stock Down 4.3 %

ZTS opened at $164.39 on Wednesday. The company has a fifty day moving average price of $166.94 and a 200-day moving average price of $176.55. The firm has a market capitalization of $73.61 billion, a P/E ratio of 30.05, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.33.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.22%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.